The European Medicines Agency (EMA) approved this Thursday the Pfizer vaccine against coronavirus for children between 5 and 11 years, a decision that will help accelerate the fight against the virus at a time when the pandemic is raging in Europe.
Using the immunizer’s trade name, the EMA said an expert panel “recommended expanding the indication for the Comirnaty vaccine to include children between 5 and 11 years old.”
This messenger RNA (ribonucleic acid) vaccine it has already been authorized to inoculate it from the age of 12 in the 27 countries of the European Union (EU).
Outside of Europe, this Pfizer immunizer has already been approved for children between 5 and 11 years old in a few countries, such as United States, Israel and Canada.
Children in this age group will receive a third of the dose supplied to the elderly, in two inoculations with three weeks between each other, explained the European regulator.
Vaccine has shown efficacy of more than 90%
This vaccine has shown an efficacy of 90.7% in a test conducted on a sample of 2,000 children between these ages, he added.
The side effects were classified between “Mild and moderate”. They can last a few days and manifest as localized pain at the site of inoculation, fatigue, headache and / or muscle pain, or a cold.
Consequently, the EMA “concluded that Comirnaty’s benefits in children from 5 to 11 years old outweigh the risks, particularly among those with comorbidities that can increase the risk of contracting a severe form of COVID-19, ″ according to the statement.
Currently, the EMA has authorized four vaccines for the general population: those of Pfizer and Moderna, of messenger RNA, and those of AstraZeneca and Johnson & Johnson, which use the “non-replicating viral vector” technique, based on adenovirus.